PROBLEM TO BE SOLVED: To provide a CML (chronic myelogenous leukemia) stem cell scavenging agent, a TKI (tyrosine kinase inhibitory drug) resistance depressant and a multi kinase inhibitory drug resistance depressant, which are safer and more effective than a TGF-β inhibitory drug, by clarifying a novel signal-transducing pathway relating to sustention of a chronic myelogenous leukemia stem cell and by selectively inhibiting the signal, and thereby, to provide a therapeutic agent of relapse CML and Ph+ALL and a preventive agent for relapse of CML and Ph+ALL.SOLUTION: A chronic myelogenous leukemia therapeutic agent comprises a selective inhibitory drug for a TGF-β-Smad signal. The therapeutic agent is obtained by a combination with a tyrosine kinase inhibitory drug or a multi kinase inhibitory drug.COPYRIGHT: (C)2014,JPO&INPIT【課題】慢性骨髄性白血病幹細胞の維持に関与する新規シグナル伝達経路を明らかにし、当該シグナルを選択的に阻害することにより、TGF-β阻害薬よりも安全かつ有効なCML幹細胞除去薬、TKI抵抗性抑制薬ならびにマルチキナーゼ阻害薬抵抗性抑制薬を提供すること。これによって、再発CML及びPh+ALLの治療薬とCML及びPh+ALLの再発予防薬を提供すること。【解決手段】TGF-β-Smadシグナルの選択的阻害薬を含有してなる、慢性骨髄性白血病治療剤。チロシンキナーゼ阻害薬またはマルチキナーゼ阻害薬と組み合わせてなる、上記治療剤。【選択図】なし
